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Abstract
Despite its frequency, psoriasis is still a difficult pathology to manage, in no 
small part due to the wide number of therapeutic choices available. These range 
from topical medicine to systemic drugs to more targeted agents such as biological 
therapies. All medical personnel involved in the treatment of psoriasis patients 
should be aware of these methods and apply them accordingly. Even though all 
patients may benefit from specific treatment options, these differ in regard to 
posology, monitoring, interactions and contraindications. Moreover, due to the 
adverse effects and drug interactions of some of these agents, not all patients are 
suitable candidates for each of therapies discussed. Therefore, nurses, trainees, 
general practitioners and dermatologists must carefully select the most appropri-
ate therapy based on the characteristics of each patient, severity of the pathology, 
comorbidities and coexistent medications. This review aims to offer an updated, 
pragmatic insight into the modern management of patients with moderate-to-
severe psoriasis.
Keywords: psoriasis, T cells, immunomodulators, keratinocytes, phototherapy, 
systemic therapies, biologic agents
1. Introduction and short history
Psoriasis is defined as chronic inflammatory systemic ailment, affecting the 
teguments foremost, and characterized by important genetic and immune constitu-
ents. The most common form is represented by psoriasis vulgaris, affecting every 
race and all ages, most often between the ages of 50 and 69 years, concerning at 
least 100 million individuals worldwide [1, 2]. It is a potentially devastating disorder 
with a progressive natural course, associated with multiple comorbidities and typi-
fied by underlying immunologic and inflammatory elements [3]. Despite it being 
a convoluted pathology with an incompletely elucidated pathogenesis, it has been 
shown that the environment, immune system and genetic predisposition all play a 
decisive role in triggering the psoriasis cascade [4]. As of today, treating psoriasis 
remains a demanding endeavour, merely attending the symptoms and ignoring the 
principal cause. Medical management is satiated by a wide variety of choices with 
fluctuating efficiency, for example, topical therapies, phototherapy, systemic drugs 
and biological agents [5]. It is fathomable that choosing the most appropriate treat-
ment scheme for each individual can oftentimes be perplexing or even dishearten-
ing. Nevertheless, the treatment involved should imply a multidisciplinary course 
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of action, with psychologists, rheumatologists and dermatologists collaborating in 
order to deliver the best possible care, with the most satisfactory outcome.
To properly understand the breakthroughs of modern treatment of psoriasis, it 
might be worthwhile to glance over the history of this complicated disease. The first 
reported cases were identified in ancient Greece, many of the description written by 
Hippocrates (460–377 BC) himself [6, 7]. Portrayals of psoriasis can also be traced 
back to the times of the Old Testament, wherein people suffering from such skin 
disorders were publicly ostracized since they were considered punished by divinity. 
Numerous historians acknowledge Celsus (ca. 25 BC–45 AD) as documenting the 
first clinical description of papulosquamous diseases, whereas Galen (133–200 AD) 
first utilized the term psoriasis [6, 8, 9]. However, his depiction was inconsistent 
regarding the disorder that we now know as psoriasis. He described it as a pruritic, 
scaly skin illness of the eyelids and scrotum, probably referred to as today as sebor-
rheic dermatitis. Nevertheless, the unselective grouping together of all inflamma-
tory skin disorders contributed to the stigmatization of psoriasis patients. During 
the Middle Ages, when it was believed that psoriasis was as contagious as leprosy, 
these patients were mandated to carry a chime or clapper that would announce their 
approach. Furthermore, they had to wear a special garment and could only eat or 
come into physical contact with others considered lepers.
In the dawn of the nineteenth century, Willan expanded on Celsus’s explana-
tions of papulosquamous afflictions by describing characteristics we know con-
sidered compatible with psoriasis. Even so, he labelled modern psoriasis as ‘lepra 
vulgaris’, which maintained the confusion between these two distinct diseases 
[6, 7, 10]. Afterwards, there was an incongruity when referring to these patholo-
gies, as authors could not properly agree on which term to use. Ultimately, Gibert 
corroborated Willan’s description with the term psoriasis, putting an end to some 
of the perplexity and guiding to an improved awareness and understanding of 
psoriatic patients. Heinrich Auspitz (1835–1886) noticed the papillary bleeding that 
appeared after removing the scale of psoriatic lesions, currently referred to as the 
Auspitz sign (or bloody dew phenomenon) [6, 7, 11, 12]. In 1877, Heinrich Köbner 
(1838–1904) defined the sign that carries his name, specifically the occurrence of 
a psoriatic lesion within the location of a physical injury. After two more decades, 
in 1898, William Munro (1863–1908) described the microabscesses that appear in 
psoriasis, otherwise known as Munro’s abscesses. The beginning of the twentieth 
century led to further advancements in the understanding of psoriatic lesions. In 
1910, Leo von Zumbusch (1874–1940) was the first to note generalized pustular 
psoriasis, now called the von Zumbusch disease [6, 13]. Among other descriptions 
was also the one of the Russian dermatologist D.L. Woronoff in 1926 regarding a 
pale halo now known as the ‘Woronoff ring’ enclosing a plaque of psoriasis [7, 14]. 
The characterization of the Auspitz sign, Köbner’s phenomenon, Munro’s abscess, 
and pustular psoriasis, as well as the Woronoff ring made it possible for practitio-
ners to more easily identify patients with psoriasis.
The next discoveries furthered our understanding of pathophysiology, especially 
concerning epidermal hyperplasia and keratinocytes’ cell cycle shortening by van 
Scott and Ekel in 1963, followed by the role of the immune system by Gubner in 
1951 and Muller in 1979 [6, 7]. However, there is still much to be learned about this 
complex disease and its intricate mechanisms.
The treatment of psoriasis also varied across the ages, from arsenic and ammoni-
ated mercury in the nineteenth century (which both had a comparable toxic poten-
tial), to chrysarobin, anthralin and coal tars in the late nineteenth and early twentieth 
centuries, reaching to corticosteroids, methotrexate and PUVA in the middle of the 
last century [6, 7, 10, 15]. In what follows, we describe the modern forms of therapy 
which have been scientifically proven to ameliorate the  symptoms in psoriasis.
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2. Management of psoriasis
In the past few years, countless achievements have been made in grasping the 
intricate physiopathological contrivances of psoriasis. Studies repeatedly demon-
strated that it is a chronic, systemic immune-mediated ailment, the dermatologic 
manifestation representing its most debilitating aspect, usually followed by joint 
involvement. However, the explicit mechanisms of this process have not been 
untangled. Even so, it appears that the myeloid dendritic cells begin producing 
interleukins such as IL-12, IL-23 and TNF-α prior to a minor traumatic injury 
that perform as chemoattractants for the T helper Th-1 and Th-17 cells [16, 17]. 
In the next step, these cells will raise the production of psoriatic cytokines such as 
IL-17 within the site of injury, hence increasing the keratinocytes’ turnover and 
eventually piloting towards the cutaneous symptoms of psoriasis [18–21]. Also, the 
proinflammatory substances may extend into the bloodstream with a significant 
influence on insulin signalling, angiogenesis, lipogenesis or adipogenesis, which 
will ultimately lead to comorbidities such as obesity and dyslipidaemia, hyperten-
sion, depression and type 2 diabetes mellitus [3, 22]. Grasping the mechanisms of 
psoriasis is the utmost step in offering the best available therapy.
Topical therapy as the only form of treatment has demonstrated a mediocre 
rate of improvement, with patients often describing ongoing clinical symptoms, 
for instance, redness, pruritus or scales [23]. One survey targeted to such patients 
showed that 40% of cases with a mild disease, circa 50% of those with moderate 
psoriasis and well above 40% with the severe form were discontented with the rec-
ommended topical therapies. The lowermost treatment satisfaction quotients were 
found in the topical medications versus systemic and phototherapy group [24]. 
Should topical therapy in itself fail to achieve the expected outcome, practitioners 
have to be ready for alternative strategies, such as systemic and biological therapies.
2.1 Topical therapy
Topical therapies are recommended in mild psoriasis, when the affected body 
surface area is below 10% [25].
2.1.1 Anthralin
Anthralin via mitochondrial dysfunction might reduce the proliferation of kera-
tinocytes and re-establish cell differentiation. As such, it is used to treat the local-
ized plaques that are covered with thick scales localized either on body or the scalp 
that have failed to clear with other treatments. It is applied on the affected areas in 
concentration of 1%, and it is left between 20 min and 1 h before removal [26].
Among the adverse effects, the common is skin irritation or staining of the 
adjoining skin [25].
2.1.2 Coal tar
Coal tar seems to reduce hyperproliferation of keratinocytes by supressing DNA 
synthesis, and it has exhibited efficacy on chronic plaque psoriasis, palmoplantar 
psoriasis or scalp psoriasis, improving the general aspect of the psoriasis plaque 
after 1 month of treatment. It appears as though the remission period of the lesions 
persists longer than that with other topical treatments [25].
Adverse effects number odour, staining, contact dermatitis, erythema and 
folliculitis.
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2.1.3 Salicylic acid
Salicylic acid triggers desquamation of corneocytes via lowering intracellular 
cohesion between the cells of the stratum corneum. It can be applied in creams, 
ointments or lotions in concentrations between 2 and 6%.
The most notable adverse effect mentioned while using salicylic acid is the 
potential systemic intoxication [28].
It is safe to utilize during pregnancy, but in children, because of the systemic 
absorption, it should be avoided [25].
2.1.4 Calcineurin
Calcineurin inhibitors like tacrolimus, pimecrolimus and sirolimus supress the 
production of the inflammatory substances that seem accountable for the skin 
lesions in psoriasis. It is found in concentration of 0.3% gel or 0.5% cream [29].
As side effects, the most common is stinging sensation or contact dermatitis.
It can be used in children older than 2 years old [25].
2.1.5 Topical retinoids tazarotene and bexarotene
Topical retinoids tazarotene and bexarotene downregulate the turnover by alter-
ing transcription of genes in keratinocytes upon transportation within the nucleus, 
after binding to retinoic acid on the cell membrane. Furthermore, it reduces the 
hyperproliferation of keratinocytes; it regulates the differentiation and reduces 
inflammation [30].
It can be applied as a cream in concentration of 0.1 and 0.05%, and when 
used on the nails, it seems to improve the onycholysis, pitting and salmon 
patches [25].
It is contraindicated during pregnancy, but it is permitted to be used in 
children [31].
2.1.6 Topical corticosteroids
Topical corticosteroids display immunosuppressive, anti-inflammatory, anti-
proliferative and vasoactive action. They are categorized based on their potency, 
from low-potency to very potent corticosteroids. When considering the potency 
and the vehicle, disease severity, patient preference and sites of lesions must be 
taken into account [25]. They can be found as creams, ointments, gel, solutions, nail 
lacquer, foams or shampoos applied on the skin, scalp or nails.
Skin atrophy, telangiectasia as well as secondary infection are the most notable 
side effects.
Corticosteroids can be used during pregnancy but are not recommended in 
children under 2 years old [32].
2.1.7 Vitamin D
Vitamin D analogues calcitriol, tacalcitol, maxacalcitol, paricalcitol and beco-
calcidiol decrease keratinocyte proliferation, inflammation or keratinization [33]. 
They can be applied on the skin, scalp or nails and are found as creams, ointments 
or scalp lotions.
The most common side effect is skin irritation. Very rare hypercalcemia, hyper-
calciuria and parathyroid hormone suppression have been described.
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Vitamin D analogues are contraindicated in patients with hypercalcemia or in 
pregnancy, but they can be used in children while not exceeding the dose of 50 g/
week [34].
2.2 Phototherapy in psoriasis
Ultraviolets either from the sun or artificial light play a significant role in treat-
ing psoriasis mainly by supressing activated T cells, independently on the cell 
subpopulation involved in the disease [25]. It has been shown that NB-UVB is the 
most utilized phototherapeutical approach, inducing clinical and histopathological 
resolution of moderate-to-severe plaque psoriasis by exerting a cytotoxic effect on 
epidermal T cells [35, 36]. This apoptotic effect on T cells depends mostly on the pen-
etration of the NB-UVB within the lesion, penetration that on the one hand depends 
on the wavelength and on the other the depth of the skin lesion [37]. Understanding 
that the T cells responsible for psoriasis are situated along the dermal-epidermal 
junction and within the epidermis, it has been determined that the optimal wave-
length spectrum should range between 290 and 313 nm [38]. Currently, NB-UVB is 
the most common approached used worldwide, and it can be regarded as the gold 
standard in therapy for treating moderate-to-severe plaque psoriasis [39].
2.3 Systemic therapies
2.3.1 Methotrexate
Methotrexate is a folic acid analogue employed in psoriasis for its anti-prolifera-
tive, anti-inflammatory and immunosuppressive actions [40].
Dosage and administration. Methotrexate comes as a self-injectable solution 
administered by the patient weekly, with the added proposal of coupling with folic 
acid supplements. Initiation dosage is typically 10–25 mg once per week. Maximum 
dose should not surpass 30 mg/week. Folate intake should be about 1–5 mg daily, 
except on the day of methotrexate intake [41].
Adverse effects. In case of pregnancy, it may lead to foetal death or to teratogenic 
effects; also, it can be toxic to the gastrointestinal tube, liver and kidneys, and it can 
cause myelosuppression, malignant lymphomas, pulmonary fibrosis, severe infec-
tions, fatigue, headaches, alopecia or oligospermia [42, 43].
Laboratory tests recommended. To start therapy with methotrexate correspond-
ingly, the following evaluations are compulsory: physical exam, patient history, 
QuantiFERON-TB Gold for latent TB infection, complete blood count with differential 
and thrombocytes count, renal function tests, hepatic enzymes and pregnancy test.
Drug interactions. Methotrexate has been shown to interact with cyclosporine, 
proton pump inhibitors, oral antibiotics, salicylates, mercaptopurine, nonsteroidal 
anti-inflammatory drugs, cisplatin, probenecid, phenylbutazone, sulfonamides, 
theophylline, live vaccines, retinoids and azathioprine [43].
As anticipated, this drug is contraindicated in pregnancy and while breastfeed-
ing due to its teratogenic effects. Therefore, the use of contraception is highly advo-
cated in the course of treatment. Other contraindications include blood dyscrasia, 
chronic liver disease, immune deficiency syndromes or alcohol abuse [44].
2.3.2 Cyclosporine
Cyclosporine is a calcineurin inhibitor agent that is used in psoriasis for its 
immunosuppressing action and its capability to prevent the T cell proliferation 
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by reversibly inhibiting the activation of CD4+ T cells, leading to a block on the 
synthesis of interleukin 2 [45].
Dosage and administration. To induct psoriasis remission, the everyday dos-
age varies between 2.5 and 5 mg/kg, administered in two divided doses each day. 
Experts recommend it not be used continuously for longer than 1 whole year [46].
Adverse effects. Among the most important reported adverse effects of cyclospo-
rine are renal toxicity, structural kidney damage, hypertension, liver toxicity, severe 
infections, high potassium levels, low magnesium levels, acne, tremors, headache, 
pneumonitis and gastrointestinal toxicity [47, 48].
Laboratory tests recommended. Physical exam, patient history, QuantiFERON-TB 
Gold for latent TB infection, renal function tests, complete blood count with 
differential and platelet count, magnesium level, potassium level, uric acid, lipids, 
glycaemia, bilirubin and liver enzymes are necessary before initiating therapy. The 
serum creatinine should be measured on two distinct occasions. Contraception has 
to be ensured.
Drug interactions. Cyclosporine interacts with a large number of drugs such as 
antibiotics (ciprofloxacin, gentamicin, tobramycin, vancomycin, trimethoprim 
with sulfamethoxazole, azithromycin, erythromycin), nonsteroidal anti-inflamma-
tory drugs, antifungals (amphotericin B, ketoconazole, fluconazole, itraconazole, 
terbinafine), ranitidine, cimetidine, birth control pills, tacrolimus, methotrex-
ate, methylprednisone, allopurinol, colchicine, fenofibrate, gemfibrozil, statins, 
calcium channel blockers, amiodarone, bromocriptine, anticonvulsants (carbam-
azepine, oxcarbazepine, phenobarbital), protease inhibitors (indinavir, nelfinavir, 
ritonavir, saquinavir) and octreotide [48].
It is contraindicated in the case of poorly controlled arterial hypertension, 
known malignancies or renal dysfunctions. As of yet, there have not been enough 
studies performed in humans to certify whether the drug affects the foetus or not. 
Nonetheless, the treatment is still to be avoided in pregnant women due to the role 
calcineurin inhibitors are believed to play in neural development. As such, cyclo-
sporine should only be used in pregnancy if the benefits justify the hypothetical 
risk to the foetus [49].
2.3.3 Acitretin
Acitretin is a retinoid agent with substantial immunomodulatory and anti-
inflammatory effects, advocated in psoriasis for its capacity to modulate the prolif-
eration and differentiation of keratinocytes [50].
Dosage and administration. Acitretin is taken in a single oral dose, alongside the 
main meal. Therapeutic dosage varies between 25 and 50 mg/day. A simultaneous 
topical therapy is also suggested due to the slow onset of action, needing as long as 
3–6 months for a maximal response to acitretin [51].
Adverse effects. It can cause serious teratogenic effects on the exposed foetus, 
mucocutaneous dryness, hypertriglyceridemia, hepatotoxicity, toxic hepatitis, 
pancreatitis, hyperostosis, intracranial hypertension, alopecia, arthralgia and 
fatigue [52].
Laboratory tests recommended. It is compulsory to take a pregnancy test before 
initiating the treatment; liver enzymes, lipid profile, renal function and complete 
blood count should also be included.
Drug interactions. Acitretin interacts with retinoic acid supplements, methotrex-
ate, doxycycline, oral retinoids and phenytoin [53].
The high teratogenicity of retinoids severely restricts their use in fertile women 
who should be appropriately counselled on the methods and importance of contra-
ception [54]. Moreover, pregnancy should be circumvented for at least 3 years after 
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halting treatment. A pregnancy test is to be performed regularly every 3 months 
during the course of therapy.
2.3.4 Fumaric acid esters and dimethyl fumarate
Fumaric acid esters and dimethyl fumarate have been employed in the treatment 
of psoriasis for five decades, with substantial outcomes for patients [55]. Seemingly, 
dimethyl fumarate affects multiple cytokines and lymphocyte pathways, i.e. inhib-
iting the nuclear translocation and the transcriptional activity of the nuclear factor 
kappa-light-chain-enhancer of activated B-cells through its interaction with the 
intracellular reduced glutathione. It also transforms the T helper cells from the Th1 
and the Th17 profile to a Th2 phenotype, subsequently reducing cytokine produc-
tion and the proliferation of epithelial cells [56].
Dosage and administration. It is available as gastro-resistant tablets, being recom-
mended to start with a low initial dose that may be subsequently increased in the 
following manner: in the first week, it is advised to take one 30 mg tablet, in the 
second week one 30 mg tablet can be taken twice daily, and during the third week 
one 30 mg tablet is taken three times per day. From the fourth week onwards, it can 
be switched to one 120 mg tablet, taken in the evening. Depending on the results, 
this dose can be increased with one 120 mg tablet per week, but the maximum daily 
dose should not exceed 720 mg [57].
Adverse effects. Among more regularly reported events are gastrointestinal 
disorders, flushing, haematological disturbances (lymphopenia, leukopenia, 
eosinophilia), loss of appetite, headache, paraesthesia, proteinuria, renal failure, 
Fanconi syndrome and fatigue [58].
Reference tests. Complete blood count, renal function and liver enzymes should 
be included.
Drug interactions. Fumaric acid esters may interact with live vaccines, metho-
trexate, retinoids, cyclosporine, aminoglycosides, lithium, diuretics and nonsteroi-
dal anti-inflammatory drugs [59].
2.3.5 Apremilast
Apremilast, operating as a selective inhibitor of phosphodiesterase 4, on the 
one hand downregulates the expression of specific proinflammatory cytokines like 
IL-17, IL-23 and TNF-α that each plays a crucial role in the pathophysiological chain 
of events in psoriasis. On the other hand, using the same mechanism, it increases 
the expression of anti-inflammatory cytokines such as IL-10 [59].
Dosage and administration. Presented in tablet form, apremilast is administered 
orally, with an indicated dose of 30 mg two times per day. The treatment should 
begin with a low starting dose of 10 mg in the morning, and then from the second 
day of therapy onward the dosage is increased daily by 10 mg until reaching the 
therapeutic dose of 30 mg twice daily [60, 61].
Adverse effects. Diarrhoea, nausea and vomiting, depression and weight loss are 
the most frequently noted adverse effects of apremilast [62].
Laboratory tests recommended. Physical exam, patient history (with an emphasis 
on psychiatric disorders such as depression), renal function and liver enzymes 
should be performed.
Drug interactions. Apremilast interacts with cytochrome P450 enzyme inducers 
such as rifampin, phenobarbital, carbamazepine and phenytoin [61].
Patients over 65 years old appear to be more vulnerable to develop the 
aforementioned side effects. Hence, supervision is very important in these 
cases, patients being warned regarding undesirable events. They should also be 
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instructed not to reduce or suspend the medication by themselves, but to address 
their treating physician [62].
2.4 Biologic therapies
2.4.1 The anti-TNF-α agents
The anti-TNF-α agents etanercept, adalimumab, infliximab and certolizumab 
have been developed to expressly inhibit the TNF-α signalling pathway, thereby 
lessening its inflammatory properties. Etanercept is a recombinant TNF-α recep-
tor that impedes TNF-α function by operating as a decoy receptor that attaches to 
TNF. Adalimumab is an entirely humanized antibody of TNF-α, where infliximab 
is a mouse-human chimeric antibody. Certolizumab represents a distinctive anti-
TNF-α antibody that does not include the Fc portion [63, 64].
Dosage and administration. Etanercept, adalimumab and certolizumab are given 
via subcutaneous injection either weekly or once every two weeks. Infliximab is 
administered via intravenous infusion every 8 weeks. Table 1 presents the dosage 
and the administration method for the abovementioned anti-TNF-α agents [65–68].
Adverse effects. Among the serious side effects encountered while using any of the 
mentioned anti-TNF-α agents are severe infections, lymphomas or other malignan-
cies and even the reactivation of the tuberculosis or hepatitis B virus. While using 
etanercept, adalimumab or certolizumab, the most usual local reactions are pain, 
swelling, haemorrhage or erythema at the place of injection; however, the intensity 
of these symptoms will diminish with continued treatment. Patients should be 
advised not to accept taking live vaccinations for the duration of the therapy. There 
have been reported cases of CNS demyelinating pathologies (e.g. multiple sclerosis, 
optic neuritis) or peripheral nerve demyelinating disease (Guillain-Barré syn-
drome). Patients are advised to suspend the therapy in these cases [3, 65–68].
Laboratory tests recommended. Physical exam and history, complete blood count, 
liver function, renal function, viral hepatitis screening and tuberculosis testing 
should be performed prior to anti-TNF-α treatment initiation.
Drug interactions. Other biologic therapies, live vaccines, anakinra and abata-
cept, were noticed to interact with anti-TNF-α drugs [65–68].
Certolizumab has been approved by the FDA for pregnant women. Data col-
lected thus far has validated neither additional teratogenic effects when compared 
to the general population, nor a greater risk of foetal death [69].
2.4.2 The anti-IL-12/23 agents
The anti-IL-12/23 agents comprise ustekinumab, guselkumab and tildraki-
zumab. Il-23 is a heterodimeric cytokine incorporating two subunits: the p19 
subunit, which is connected to the p40 subunit, the latest being shared with IL-12. 
Il-23 is the main actor prompting the activation of the T helper 17 inflammatory 
pathway, whereas IL-12 plays the chief role in Th-1 differentiation and prolifera-
tion. Ustekinumab is a biologic agent aiming for the p40 common domain of IL-12 
and IL-23, hence preventing their interaction with their receptor. Contrariwise, 
guselkumab and tildrakizumab target the p19 subunit of IL-23, thus obstructing the 
signalling pathway associated with the immunopathogenesis of psoriasis [70–72].
Dosage and administration. Ustekinumab, guselkumab and tildrakizumab are 
delivered as prefilled syringes with subcutaneous administration. The induction 
phase lasts 1 month, being then ensued by the maintenance phase. In this phase, an 
injection is administered once every 8 or 12 weeks. Table 2 presents the respective 
posology for the aforementioned biologic agents [73–75].
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Adverse effects. The most notable and grave adverse effects include severe infec-
tions, tuberculosis, malignancies, hypersensitivity reactions, headache, fatigue, 
injection site reaction, joint pain and gastroenteritis [73–75].
Laboratory tests recommended. Physical exam, patient history, complete blood 
count, liver function, renal function and tuberculosis testing have to be performed 
before treatment can begin.
Drug interactions. These agents have been noticed to interact with live vaccines. 
Therefore, it is contraindicated to receive any such vaccines during therapy [3, 73–75].
2.4.3 Ixekizumab, secukinumab and brodalumab
Ixekizumab, secukinumab and brodalumab are systemic anti-IL-17 agents 
that carry out their roles by expressly inhibiting the IL-17 signalling pathway. 
Ixekizumab is a humanized IgG4 antibody with a high affinity for IL-17A [76]. 
Secukinumab is a fully human IgG1 antibody that also blocks IL-17A. Last but 
not least, brodalumab is a fully human IgG2 antibody that impedes the IL-17 
pathway at the receptor level, i.e. by binding to the IL-17RA, a receptor shared by 
IL-17A and other IL-17 cytokines. For this reason, its effect is broader but more 
unspecific [77].
Dosage and administration. Ixekizumab, secukinumab and brodalumab are 
administered as prefilled subcutaneous injections. The induction phase varies from 
3 to 12 weeks, followed by the maintenance phase with one or two injections either 
every second or monthly. Table 3 illustrates the posology of these therapies [78–80].
Adverse effects. Anti-IL-17 agents may cause serious infections, headache, joint 
pain, hypertension, diarrhoea, injection site reaction (oedema, pain, erythema, 
ecchymosis), musculoskeletal pain and hypersensitivity reactions [81].
Laboratory tests recommended. Physical exam, patient history, complete blood 
count, liver function, renal function and tuberculosis testing must be performed 
before these therapies as well.
Drug interaction. These agents may interact with drugs that are metabolized by 
cytochrome P450, e.g. warfarin or cyclosporine [78–80].
Biologic agent Posology
Ustekinumab 45 mg × 1 administered at weeks 0 and 4 and at every 12 weeks subsequently
Guselkumab 100 mg × 1 administered at weeks 0 and 4 and at every 8 weeks afterwards
Tildrakizumab 100 mg × 1 administered at week 0 and 4 and every 12 weeks thereafter
Table 2. 
Anti-IL-22/anti-IL-23 agents. Posology.
Biologic agent Posology
Etanercept 50 mg × 1 twice a week during the induction phase (the first 3 months), thereafter only 
one injection weekly
Adalimumab 40 mg × 2 at week 0, afterwards 40 mg × 1 administered every 14 days
Infliximab 5 mg/kg is administered via intravenous infusion at weeks 0, 2 and 6 and after that every 
8 weeks
Certolizumab 200 mg × 2 administered subcutaneously at weeks 2 and 4, followed by a 200 mg × 1 dose 
weekly
Table 1. 
Anti-TNF-α agents. Posology.
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3. Biological therapies and pregnancy
Despite their presently being no curative remedies for psoriasis, a wide assort-
ment of specific molecular agents exist that are able to ameliorate the symptoms 
and produce remission. Delivering any of the aforementioned drugs varies pri-
marily on the proficiency of the treating practitioner and only afterwards on the 
patient’s personal choice. It is of utmost importance that women during childbear-
ing age are aware that no studies have been conducted on whether or not these 
therapies are safe to use while pregnant. Consequently, should any of the biological 
treatments mentioned except for certolizumab be taken, they must be discontinued 
prior to conceiving a child. Considering certolizumab, as of writing this chapter, it 
is ostensibly the only discovered biological agent that fails to cross the maternal-pla-
cental barrier, and no adverse or teratogenic consequences were discovered if taken 
while pregnant [69]. In Table 4, we illustrate the minimal time interval suggested 
between discontinuing the medication and child conception [82].
4. Conclusions
Psoriasis is a debilitating disease with the potential to cause severe psychologi-
cal damage. In spite of the plentiful advances vis-à-vis treatment, we are still a 
long way off from obtaining an actual cure. It is crucial to remember that current 
management strategies only address the symptoms, and not the cause. Therefore, 
Therapeutic agent Contraception
Methotrexate During pregnancy and at least 3–6 months after
Cyclosporine Contraception only during the therapy
Acitretin During pregnancy and at least 3 years after
Fumaric acid esters During pregnancy and at least 2 weeks after
Apremilast During pregnancy and 28 days after
Adalimumab During pregnancy and minimum 5 months after
Etanercept During pregnancy and 3 weeks after
Ustekinumab During pregnancy and at least 15 weeks after
Ixekizumab During pregnancy and at least 6 months after
Secukinumab During pregnancy and minimum 20 weeks after
Table 4. 
Systemic therapy and pregnancy interval.
Biologic agent Posology
Ixekizumab 80 mg × 2 at week 0 followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12 and at every 
4 weeks afterwards
Secukinumab 150 mg × 2 at weeks 0, 1, 2, 3 and 4 and after the induction phase, 150 mg × 2 is 
administered once every month
Brodalumab 210 mg × 1 at week 0, 1 and 2, followed by 210 mg × 1 administered every 2 weeks 
subsequently
Table 3. 
Anti-IL-17 agents. Posology.
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those affected should be closely monitored even in the case of stationary disease or 
have regression. Moreover, not all therapies correspond to every patient due to pos-
sible comorbidities and drug interactions, and thus the notion of a miracle agent in 
psoriasis appears more and more illusory. This chapter aimed to provide a synopsis 
of modern treatment options of psoriasis, so that practitioners are sensitized of 
their uses, contraindications and adverse effects in order to choose the best available 
strategy.
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